Back
Coefficient Giving - 1Day Sooner General Support November 2020
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: Coefficient Giving
This grant record is tangentially relevant to AI safety via biosecurity and pandemic preparedness; 1Day Sooner's work on human challenge trials accelerates vaccine development, a concern intersecting with biological risk reduction efforts.
Metadata
Importance: 12/100organizational reportreference
Summary
This page documents an Open Philanthropy grant to 1Day Sooner, an organization advocating for human challenge trials in vaccine development. The grant reflects Open Philanthropy's broader commitment to global health R&D, supporting organizations that accelerate vaccine and treatment development for underserved diseases.
Key Points
- •Open Philanthropy provided general support funding to 1Day Sooner in November 2020, an advocacy group promoting human challenge trials for COVID-19 vaccines.
- •The grant falls under Open Philanthropy's Science and Global Health R&D portfolio, which has distributed $550M+ across 330+ grants since 2016.
- •The fund prioritizes diseases disproportionately affecting the poor (TB, malaria) and high-risk transformational science that is underfunded by government and private sectors.
- •1Day Sooner advocates for accelerated vaccine testing methodologies, relevant to AI safety discussions around pandemic preparedness and biosecurity.
- •The page is now hosted under 'Coefficient Giving,' indicating a rebranding or restructuring of the Open Philanthropy global health funding arm.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| 1Day Sooner | Organization | 60.0 |
Cached Content Preview
HTTP 200Fetched Mar 15, 20268 KB
Science and Global Health R&D | Coefficient Giving
Skip to Content
Science and Global Health R&D
We support research and development into new tools to improve global health.
Contents
About the Fund
Research & Updates
Featured Grants
About the Fund
Team
Jacob Trefethen
Managing Director
Chris Somerville
Program Director
Heather Youngs
Program Director
Katharine Collins
Senior Program Officer
Ray Kennedy
Senior Program Officer
Aisling Leow
Associate Program Officer
Rafael Dib
Senior Program Associate
Partners
Good Ventures
Patchwork Collective
Private funders (x3)
Interested in learning more or joining the fund? Reach out to partnerwithus@coefficientgiving.org .
Health technologies like vaccines and drugs save millions of lives around the world. Yet many cures remain undiscovered. Government and private sector funders do not always prioritize research and development (R&D) that could help the most people live long and healthy lives.
Diseases like tuberculosis, malaria, and rheumatic heart disease that primarily affect the world’s poorest people receive much less R&D spending relative to their health burdens than diseases affecting the wealthy. High-risk, transformational science often goes unfunded, too.
We are particularly interested in supporting products or fields where progress has stalled, where additional resources could accelerate breakthrough discoveries and new tools for global health.
We have supported scientific research for human health since 2016, expanding our work in global health R&D in 2023. Our work includes:
Transformative basic research and tool development aimed at answering fundamental questions about biology and human health.
Preclinical and clinical studies to develop and test new treatments , vaccines , diagnostics , and other preventive technologies .
Implementation research , technical assistance , and market-shaping initiatives to help health systems make use of the best knowledge and tools available, and expand the availability of lifesaving technologies.
Research & Updates
Prev
Next
Impact Story
How Neil King and David Baker Are Using AI To Create More Effective Vaccines
In October 2024, our longtime grantee David Baker won the Nobel Prize in Chemistry for his groundbreaking work in protein design. We wanted to take the opportunity to highlight his work and some of its practical applications, such as enabling better vaccines.
Read more
B
... (truncated, 8 KB total)Resource ID:
0f727d3eff4f9441 | Stable ID: Nzk2MjEwOW